Brandes A A, Pasetto L M
Divisione di Oncologia Medica, Azienda Ospedale, Universit di Padova, Padova, Italy.
Forum (Genova). 2000 Apr-Jun;10(2):121-31.
The incidence of central nervous system neoplasias ranges from 3.8 to 5.1 cases per 100,000 inhabitants. In the presence of recurrence, the treatment is problematic; chemotherapy is experimental, primarily because the response is palliative and of limited duration. This article analyses the new drugs that have been introduced in the treatment of these patients in the latest years, the objective response, the time to progression and the mean survival time. The most encouraging results to date come from studies of temozolomide, which is one of the most active and best tolerated drugs in recent years. New approaches to the chemotherapy treatment are necessary. Enrolment of patients into rigorous, well-conducted, clinical trials, both at tumour diagnosis and after tumour recurrence, will generate new information regarding investigational therapies and may offer improved therapies for patients with malignant gliomas.
中枢神经系统肿瘤的发病率为每10万居民中有3.8至5.1例。出现复发时，治疗存在问题；化疗是试验性的，主要是因为其反应是姑息性的且持续时间有限。本文分析了近年来用于治疗这些患者的新药、客观反应、进展时间和平均生存时间。迄今为止最令人鼓舞的结果来自替莫唑胺的研究，它是近年来活性最强且耐受性最佳的药物之一。化疗治疗需要新的方法。在肿瘤诊断时以及肿瘤复发后，让患者参加严格、实施良好的临床试验，将产生有关研究性疗法的新信息，并可能为恶性胶质瘤患者提供更好的治疗方法。
